Oral Wegovy Weight Loss Calculator
Project your expected weight loss with oral semaglutide 25mg based on OASIS 1 trial data
Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.
Frequently Asked Questions
In the OASIS 1 trial, oral semaglutide 25mg daily produced approximately 14% body weight loss at 68 weeks.
Both contain semaglutide. Oral Wegovy is a daily 25mg pill; injectable Wegovy is a weekly 2.4mg injection. Injectable achieved ~15% loss vs ~14% for oral at 68 weeks.
Oral semaglutide has ~1% bioavailability. The 25mg oral dose delivers roughly the same active drug as the 2.4mg injectable dose.
The FDA approved oral semaglutide for weight management in December 2025 based on the OASIS 1 trial.
Yes. Projections are derived from the OASIS 1 clinical trial (Knop et al., Lancet 2023).
Sources
- Knop FK, et al. Oral semaglutide 50 mg taken once daily in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705-719. Link
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA.gov. Link
Methodology
This calculator projects weight loss using piecewise linear interpolation of OASIS 1 trial timepoints: ~5% at 12 weeks, ~9% at 24 weeks, ~12% at 36 weeks, ~13% at 52 weeks, ~14% at 68 weeks. Projections represent population averages. Individual results vary.
Oral Wegovy (semaglutide 25mg daily pill) produced ~14% body weight loss at 68 weeks in the OASIS 1 trial. Comparable to injectable Wegovy (~15%). Requires fasting: take on empty stomach with minimal water, 30 min before food.
What else do you want to know?
Ask Pulse anything.